EOC317
Cat. No.:YN440359
产品名称: | EOC317 |
CAS No.: | 939805-30-8 |
Chemical Name: | N-[4-[4-amino-6-(methoxymethyl)-7-(4-morpholinylmethyl)pyrrolo[2,1-f][1,2,4]triazin-5-yl]-2-fluorophenyl]-N′-[2-fluoro-5-(trifluoromethyl)phenyl]-urea |
Synonyms: | ACTB-1003 |
分子量: | 591.53 |
分子式: | C₂₇H₂₆F₅N₇O₃ |
SMILES: | O=C(NC1=CC(C(F)(F)F)=CC=C1F)NC2=CC=C(C3=C4C(N)=NC=NN4C(CN5CCOCC5)=C3COC)C=C2F |
存储: | Please store the product under the recommended conditions in theCertificate of Analysis. |
运输: | Room temperature in continental US; may vary elsewhere. |
产品描述: | EOC317 (ACTB-1003) 是口服可用的激酶抑制剂,抑制FGFR1,VEGFR2和Tie-2的IC50值分别为6,2 和 4 nM。 |
IC50和靶点: | [{name:"FGFR1:6 nM (IC50)"},{name: "VEGFR2:2 nM (IC50)"},{name: "Tie-2:4 nM (IC50)"}] |
In Vitro: | |
In Vivo: | |
Clinical Trial: | |
Solvent & Solubility: |
Patel, K., Fattaey, A., and Burd, A.ACTB-1003: An oral kinase inhibitor targeting cancer mutations (FGFR), angiogenesis (VEGFR2, TEK), and induction of apoptosis (RSK and p70S6K)J. Clin. Oncol.28(15_suppl),e13665-e13665(2010)